妊娠期甲型肝炎疫苗接种率与安全性:疫苗安全数据链研究
该回顾性队列纳入2004至2015年疫苗安全数据链中666,233例活产妊娠,评估妊娠期甲肝疫苗接种率及母婴安全结局。接种率为1.7/1000(n=1140),多发生在妊娠前六周;接种与妊娠高血压、妊娠糖尿病、子痫前期/子痫、剖宫产、早产和低出生体重无显著关联,但与小于胎龄儿存在统计学显著关联(aOR 1.32,95%CI 1.09-1.60,p=0.004),作者认为可能由未测量混杂所致,需进一步研究。
要点
- 妊娠期甲肝疫苗接种率为1.7/1000,仅不足3%的接种者有ICD确认的感染风险因素。
- 接种与妊娠高血压、糖尿病、子痫前期/子痫、剖宫产、早产和低出生体重无显著关联。
- 接种与小于胎龄儿存在显著关联(aOR 1.32,95%CI 1.09-1.60,p=0.004),可能为未测量混杂。
核心结论
- 妊娠期甲肝疫苗接种率低,且少有记录在案的接种风险因素。
- 接种未增加所评估的多项母婴不良结局风险,但与小于胎龄儿的关联需进一步探索。
研究设计与样本
- 回顾性队列研究,纳入疫苗安全数据链(VSD)2004至2015年活产妊娠666,233例。
- 比较妊娠期甲肝疫苗暴露者与其他疫苗暴露者及无疫苗暴露者,采用调整比值比(OR)描述关联。
主要发现
- 甲肝疫苗接种率为1.7/1000(n=1140),最常见于妊娠前六周。
- 不足3%的暴露者有ICD确认的甲肝感染风险因素。
- 妊娠期甲肝疫苗暴露与妊娠高血压、妊娠糖尿病、子痫前期/子痫、剖宫产、早产和低出生体重无显著关联。
- 妊娠期甲肝疫苗暴露与小于胎龄儿存在统计学显著关联(aOR 1.32,95%CI 1.09-1.60,p=0.004)。
临床怎么用
- 妊娠期甲肝疫苗接种率低,应关注有感染风险孕妇的接种评估。
- 现有数据未显示接种增加多数母婴不良结局风险,但小于胎龄儿关联需个体化权衡。
局限性
- 小于胎龄儿关联可能由未测量混杂所致,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Infection with hepatitis A virus (HAV) during pregnancy, although uncommon, is associated with gestational complications and pre-term labor. Hepatitis A vaccine (HepA) is recommended for anyone at increased risk for contracting hepatitis A, including women at risk who are also pregnant. Limited data are available on the safety of maternal HepA vaccination. OBJECTIVES: Assess the frequency of maternal HepA receipt and evaluate the potential association between maternal vaccination and pre-specified maternal and infant safety outcomes. METHODS: A retrospective cohort of pregnancies in the Vaccine Safety Datalink (VSD) resulting in live births from 2004 through 2015 was included. Pregnancies with HepA exposure were compared to those with other vaccine exposures, and to those with no vaccine exposures. Risk factors for contracting hepatitis A were identified up to one-year prior to or during the pregnancy using ICD-9 codes. Maternal and fetal adverse events were evaluated according to maternal HepA exposure status. Adjusted odds ratio (OR) were used to describe the association. RESULTS: Among 666,233 pregnancies in the study period, HepA was administered at a rate of 1.7 per 1000 (n = 1140), most commonly within the first six weeks of pregnancy. Less than 3% of those exposed to HepA during pregnancy had an ICD-confirmed risk factor. There were no significant associations between HepA exposure during pregnancy and gestational hypertension, gestational diabetes, pre-eclampsia/eclampsia, cesarean delivery, pre-term delivery, and low birthweight. There was a statistically significant association between HepA exposure during pregnancy and small-for-gestational age (SGA) infants (aOR 1.32, [95% CI 1.09, 1.60], p = 0.004). CONCLUSIONS: The rate of maternal HepA vaccination was low and rarely due to documented risk factors for vaccination. HepA vaccination during pregnancy was not associated with an increased risk for a range of adverse events examined among pregnancies resulting in live births, but an identified association between maternal HepA and SGA infant outcomes, while likely due to unmeasured confounding, warrants further exploration.
引用
- Groom HC, Smith N, Irving SA, et al. Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2019. PMID: 31548013. doi:10.1016/j.vaccine.2019.09.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。